|
Name |
dankasterone B
|
Molecular Formula | C28H42O3 | |
IUPAC Name* |
(1R,4R,9R,10R,13R,14R)-14-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-9,13-dimethyltetracyclo[8.7.0.01,13.04,9]heptadecane-3,6,17-trione
|
|
SMILES |
C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CCC(=O)[C@@]23[C@@]1(CC[C@@H]2[C@]4(CCC(=O)C[C@H]4C(=O)C3)C)C
|
|
InChI |
InChI=1S/C28H42O3/c1-17(2)18(3)7-8-19(4)21-9-10-25(31)28-16-23(30)22-15-20(29)11-13-26(22,5)24(28)12-14-27(21,28)6/h7-8,17-19,21-22,24H,9-16H2,1-6H3/b8-7+/t18-,19+,21+,22-,24+,26-,27+,28-/m0/s1
|
|
InChIKey |
GERUCBMNWOYIOR-NLEPFULASA-N
|
|
Synonyms |
dankasterone B; CHEMBL399917
|
|
CAS | NA | |
PubChem CID | 24179239 | |
ChEMBL ID | CHEMBL399917 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 426.6 | ALogp: | 5.1 |
HBD: | 0 | HBA: | 3 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 51.2 | Aromatic Rings: | 4 |
Heavy Atoms: | 31 | QED Weighted: | 0.502 |
Caco-2 Permeability: | -5.062 | MDCK Permeability: | 0.00003450 |
Pgp-inhibitor: | 0.762 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.388 |
30% Bioavailability (F30%): | 0.968 |
Blood-Brain-Barrier Penetration (BBB): | 0.276 | Plasma Protein Binding (PPB): | 81.98% |
Volume Distribution (VD): | 1.192 | Fu: | 2.01% |
CYP1A2-inhibitor: | 0.024 | CYP1A2-substrate: | 0.722 |
CYP2C19-inhibitor: | 0.167 | CYP2C19-substrate: | 0.963 |
CYP2C9-inhibitor: | 0.359 | CYP2C9-substrate: | 0.382 |
CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.688 |
CYP3A4-inhibitor: | 0.789 | CYP3A4-substrate: | 0.884 |
Clearance (CL): | 3.626 | Half-life (T1/2): | 0.714 |
hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.491 |
Drug-inuced Liver Injury (DILI): | 0.199 | AMES Toxicity: | 0.008 |
Rat Oral Acute Toxicity: | 0.942 | Maximum Recommended Daily Dose: | 0.36 |
Skin Sensitization: | 0.165 | Carcinogencity: | 0.008 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.041 |
Respiratory Toxicity: | 0.178 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002480 | 0.680 | D06JPB | 0.426 | ||||
ENC003940 | 0.532 | D0G8OC | 0.414 | ||||
ENC004615 | 0.523 | D0G5CF | 0.395 | ||||
ENC004905 | 0.487 | D0N1TP | 0.307 | ||||
ENC006033 | 0.482 | D0K5WS | 0.286 | ||||
ENC002665 | 0.464 | D0Q6NZ | 0.282 | ||||
ENC003678 | 0.462 | D0IX6I | 0.281 | ||||
ENC004906 | 0.457 | D0EP0C | 0.279 | ||||
ENC003120 | 0.457 | D08SVH | 0.277 | ||||
ENC004022 | 0.451 | D04DJN | 0.277 |